This page brings together the European Medicines Agency's (EMA) latest information on diabetes. It lists:
Ebymect is a diabetes medicine that is used, together with diet and exercise in adults with type 2 diabetes. It contains the active substances dapagliflozin and metformin. Ebymect is used: on its own...
Edistride is a medicine used to treat type 2 diabetes, chronic (long-term) heart failure and chronic kidney disease. In type 2 diabetes, Edistride is used in adults and children from 10 years of age...
Forxiga is a medicine used to treat type 2 diabetes, chronic (long-term) heart failure and chronic kidney disease. In type 2 diabetes, Forxiga is used in adults and children from 10 years of age...
Xigduo is a diabetes medicine used, together with diet and exercise in adults with type 2 diabetes. It contains the active substances dapagliflozin and metformin. Xigduo is used: on its own in...
This is a summary of the European public assessment report (EPAR) for Qtern. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is...
Four new medicines recommended for approval EMA’s human medicines committee (CHMP) recommended granting a marketing authorisation for Sotyktu (deucravacitinib) for the treatment of moderate to severe plaque psoriasis in adults, a skin disease...
Five new medicines recommended for approval EMA’s human medicines committee (CHMP) recommended five medicines for approval at its December 2022 meeting. The CHMP recommended granting a conditional marketing authorisation for the advanced therapy...
Nine new medicines recommended for approval EMA’s human medicines committee (CHMP) recommended nine medicines for approval at its May 2022 meeting. A recommendation for marketing authorisation was adopted for Cevenfacta (eptacog beta (activated))...
EMA’s human medicines committee (CHMP) has given a recommendation for two diabetes mellitus treatments, Actrapid and Insulatard, for use outside the European Union (EU). EMA is committed to supporting global regulatory capacity building and...
EMA’s human medicines committee (CHMP) recommended thirteen medicines for approval at its February 2022 meeting. The CHMP gave a positive opinion for Kimmtrak * (tebentafusp) for the treatment of uveal melanoma, a type of eye cancer. Kimmtrak was...
EMA’s human medicines committee (CHMP) recommended seven medicines for approval at its January 2022 meeting. The antiviral Paxlovid (PF-07321332 / ritonavir) received a positive opinion from the Committee for a conditional marketing authorisation...